KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Invested Capital (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Invested Capital for 6 consecutive years, with $964.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 12.23% year-over-year to $964.0 million, compared with a TTM value of $964.0 million through Sep 2025, down 12.23%, and an annual FY2024 reading of $1.1 billion, down 11.53% over the prior year.
  • Invested Capital was $964.0 million for Q3 2025 at AbCellera Biologics, down from $1.0 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $1.3 billion in Q3 2022 and bottomed at $964.0 million in Q3 2025.
  • Average Invested Capital over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
  • The sharpest move saw Invested Capital skyrocketed 1060.11% in 2021, then dropped 12.66% in 2025.
  • Year by year, Invested Capital stood at $1.0 billion in 2021, then grew by 21.82% to $1.3 billion in 2022, then fell by 5.85% to $1.2 billion in 2023, then decreased by 11.53% to $1.1 billion in 2024, then fell by 9.41% to $964.0 million in 2025.
  • Business Quant data shows Invested Capital for ABCL at $964.0 million in Q3 2025, $1.0 billion in Q2 2025, and $1.0 billion in Q1 2025.